Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Antimicrobial Susceptibility Testing Market Top Players and Business Trends

(PharmaNewsWire.Com, September 03, 2021 ) According to the new market research report Antimicrobial Susceptibility Testing Market is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period.

Download PDF Brochure:

Growth in this market is primarily driven by the rising incidence of infectious diseases; technological advancements towards the development of rapid AST technologies; increased funding, research grants, and public-private investments; growing government initiatives to detect and control antimicrobial-resistant species; and the emergence of multidrug resistance due to drug abuse.

The competitive landscape includes the analysis of the key growth strategies adopted by major players between 2017–2020 to expand their global presence and increase their market shares in the antimicrobial susceptibility testing market. The key growth strategies adopted by the top players in the market include product launches and approvals, agreements, expansions, and acquisitions. Product approvals and launches were the most widely adopted growth strategies by market players in the last three years to garner a larger share of the market. In 2019, the antimicrobial susceptibility testing market was dominated by bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), and Bio-Rad Laboratories, Inc. (US).

bioMérieux SA (France) is a leader in the global AST market. bioMérieux is a developer of innovative solutions for clinical diagnostics and industrial microbiological control in fields such as the agri-food sector, environmental monitoring, and veterinary diagnostics. The comprehensive range of products, high focus on R&D (to deliver novel products in the market), and strong geographical presence are the key factors contributing to the major market share of the company in the AST market.

The company has focused extensively on R&D efforts in the field of antimicrobial resistance, with around 75% of the company’s R&D budget dedicated to antimicrobial resistance. This heavy investment in R&D is driving the company’s launch of new and technologically improved products. For instance, in 2019, the company launched four new ETEST, namely, ETEST Meropenem/Vaborbactam, ETEST Telavancine, ETEST Imipenem/Relebactam, and ETEST Eravacycline. Moreover, in 2019, the company also introduced a new version of the ETEST Piperacilline Tazobactam in the market.

BD (US) has a wide range of product offerings in the antimicrobial susceptibility testing market, including manual and automated susceptibility testing products. The company’s flagship product─ Phoenix automated antimicrobial susceptibility testing system–is among the most widely used systems in the AST market. The company is focused on innovations and improving the quality of its products with increasing investment in its R&D department. BD’s global footprint allows it to cater to a customer base across 190+ countries such as Germany, the UK, New Zealand, Australia, and the US.

Request For Report Sample:

Thermo Fisher is among the leading players in the field of healthcare and life science research and applied sciences. The company possesses a robust product portfolio in the antimicrobial susceptibility testing segment and a significant market presence globally, along with strong sales and distribution networks in over 150 countries. The company provides for a wide range of automated, manual, and custom antimicrobial susceptibility testing products and offers the most recently approved FDA-cleared antimicrobials for susceptibility testing. The company primarily focuses on organic growth strategies such as product launches and enhancements to provide high-quality antimicrobial testing solutions to cater to the increasing demand for AST products to fight against antimicrobial resistance.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441


Mr. Aashish Mehra


Source: EmailWire.Com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today! is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC